Evidence map›Paper›PMID 34958974›Full record

ArticleTransplantation and cellular therapy2022

Antibiotic Exposure, Not Alloreactivity, Is the Major Driver of Microbiome Changes in Hematopoietic Cell Transplantation.

Rajat Bansal, Heekuk Park, Cristian C Taborda, Christian Gordillo, Markus Y Mapara, Amer Assal, Anne-Catrin Uhlemann, Ran Reshef

Open access · hybridAbstract read
In one paragraph

Article in Transplantation and cellular therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. GutBlood neoplasia · 2025
    Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Rajat BansalBlood and Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York, New York; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center.
Heekuk ParkDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, New York.
Cristian C TabordaColumbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York.
Christian GordilloBlood and Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York, New York; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York.
Markus Y MaparaBlood and Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York, New York; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York.
Amer AssalBlood and Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York, New York.
Anne-Catrin UhlemannDivision of Infectious Diseases, Columbia University Irving Medical Center, New York, New York.
Ran ReshefBlood and Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York, New York; Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, New York. Electronic address: rr3036@cumc.columbia.edu.
Columbia University Irving Medical Center · US

Funding

Carbapenem-resistant bacterial colonization and infection after liver transplantR01AI116939 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI UHLEMANN, ANNE-CATRIN · 2015 to 2019
$2.4M
Effector T-cell trafficking in graft-versus-host diseaseR01HL143424 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RESHEF, RAN · 2019 to 2023
$2.0M
NHLBI NIH HHS R01 HL143424NIAID NIH HHS R01 AI116939
6 · The paper itself

Abstract

Both autologous hematopoietic cell transplantation (auto-HCT) and allogeneic hematopoietic cell transplantation (allo-HCT) are associated with significant alterations in the intestinal microbiome. The relative contributions of antibiotic use and alloreactivity to microbiome dynamics have not yet been elucidated, however. There is a lack of data on the kinetics of microbiome changes beyond 30 days post-transplantation and how they might differ between different transplantation modalities. A direct comparison of the differential effects of auto-HCT and allo-HCT on the microbiome may shed light on these dynamics. This study was conducted to compare intestinal microbial diversity between auto-HCT recipients and allo-HCT recipients from pre-transplantation to 100 days post-transplantation, and to examine the effect of antibiotics, transplant type (auto versus allo), and conditioning regimens on the dynamics of microbiome recovery. We conducted a longitudinal analysis of changes in the intestinal microbiome in 35 patients undergoing HCT (17 auto-HCT, 18 allo-HCT) at 4 time points: pre-conditioning and 14, 28, and 100 days post-transplantation. Granular data on antibiotic exposure from day -30 pre-transplantation to day +100 post-transplantation were collected. Pre-transplantation, allo-HCT recipients had lower α-diversity in the intestinal microbiome compared with auto-HCT recipients, which correlated with greater pre-transplantation antibiotic use in allo-HCT recipients. The microbiome diversity declined at days +14 and +28 post-transplantation in both cohorts but generally returned to baseline by day +100. Conditioning regimen intensity did not significantly affect post-transplantation α-diversity. Through differential abundance analysis, we show that commensal bacterial taxa involved with maintenance of gut epithelial integrity and production of short-chain fatty acids were depleted after both auto-HCT and allo-HCT. In our dataset, antibiotic exposure was the major driver of post-transplantation microbiome changes rather than alloreactivity, conditioning intensity, or immunosuppression. Our findings also suggest that interventions to limit microbiome injury, such as limiting the use of broad-spectrum antibiotics, should target the pre-transplantation period and not only the peri-transplantation period.

Indexed as

Gastrointestinal MicrobiomeHematopoietic Stem Cell TransplantationAnti-Bacterial AgentsHumansTransplantation ConditioningTransplantation, HomologousAnti-Bacterial AgentsAllogeneic transplantationAntibioticsAutologous transplantationMicrobiome

Identifiers

PMID34958974
PMCPMC8923982
OpenAlexW4200337821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.